We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pramlintide (amylin analog)
An FDA-approved synthetic analog of the beta-cell hormone amylin (brand Symlin), injected before meals as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Honest appraisal: this is a real prescription drug, not a supplement, with genuine but modest efficacy — roughly a 0.3-0.5% HbA1c reduction and ~1-2.6 kg weight loss as an insulin adjunct. It carries a BOXED WARNING for severe insulin-induced hypoglycemia (especially in type 1 diabetes), commonly causes nausea, and requires reducing mealtime insulin when starting. Listed here for reference only; not a supplement and not auto-recommended.
Prescription medication — not a dietary supplement
Pramlintide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Pramlintide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1997–2023.
Based on 68 studies · 5 meta-analyses · 61 RCTs
Confidence
High confidenceBy outcome
Scores Moderate (5) as an FDA-approved drug with multiple 52-week phase-3 RCTs and meta-analyses confirming real but modest benefits, offset by a boxed hypoglycemia warning.
69 rigorous studies
64 randomized trials · 4 meta-analyses · 4 systematic reviews
Our evidence rating for Pramlintide is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
5 trials ongoing or recruiting · 44 completed on ClinicalTrials.gov
13 of the completed trials have posted results
Registered trials show research momentum for Pramlintide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Pramlintide is a soluble, non-aggregating synthetic analog of amylin — the 37-amino-acid beta-cell hormone that is co-secreted with insulin in response to meals.
It is a PRESCRIPTION DRUG, not a dietary supplement: branded as Symlin, it was approved by the US FDA in March 2005 as a subcutaneous, pre-meal injection used as an adjunct to mealtime insulin in patients with type 1 diabetes, and in patients with type 2 diabetes using mealtime insulin (with or without metformin and/or a sulfonylurea).
Mechanistically, amylin complements insulin in postprandial glucose regulation: it suppresses post-meal glucagon secretion, slows gastric emptying, and promotes satiety/reduces food intake. Pramlintide reproduces these effects in humans.
The evidence base is real and consists of multiple double-blind, placebo-controlled phase-3 RCTs plus meta-analyses, but the magnitude of benefit is modest.
In type 1 diabetes, two 52-week RCTs (Ratner, n=651; Whitehouse, n=480) showed placebo-corrected HbA1c reductions of roughly 0.3-0.5% with a small accompanying weight loss instead of the weight gain seen on placebo, without an overall increase in severe hypoglycemia across the full study period.
In type 2 diabetes, a 52-week RCT (Hollander, n=656) showed a sustained ~0.6% HbA1c reduction at 120 µg twice daily with ~1.4 kg weight loss vs ~0.7 kg gain on placebo, and shorter trials in patients on basal insulin (Riddle 2007/2009) reproduced a modest HbA1c benefit with no weight gain.
A type-1-diabetes meta-analysis (Qiao 2017, 10 RCTs, n=3,297) confirmed significantly lower HbA1c, postprandial glucose, insulin requirement and body weight, at the cost of more nausea, vomiting, anorexia and early hypoglycemia.
A type-2/obesity meta-analysis (Singh-Franco 2011) found a small HbA1c reduction (-0.33%) and modest weight loss (~-2.6 kg), with ~1.8× more nausea. For obesity without diabetes, a 12-month RCT (Smith/Aronne, n=411) showed sustained but modest placebo-corrected weight loss (~6-7 kg at month 12).
The honest counterweight: pramlintide carries a BOXED WARNING for severe insulin-induced hypoglycemia — because it is used alongside insulin, the most serious risk is severe hypoglycemia, particularly in type 1 diabetes and especially in the first weeks, which is why mealtime insulin must be reduced (often by ~50%) when starting and blood glucose closely monitored.
Nausea is the most common side effect, usually mild-to-moderate and concentrated in the first weeks. It must be injected separately from insulin (they cannot be mixed in one syringe). It should be used only under a clinician's care, for a genuine medical indication.
A synthetic analog of the beta-cell hormone amylin that activates the amylin receptor (the calcitonin receptor complexed with a receptor-activity-modifying protein, RAMP), largely via centrally-mediated effects — the upstream target driving its actions on glucagon, gastric emptying and satiety.
Suppresses the inappropriate post-meal rise in glucagon, reducing hepatic glucose output and blunting post-meal glucose excursions — complementing the action of mealtime insulin.
Delays gastric emptying so that nutrient (glucose) entry into the circulation is slowed, smoothing postprandial glucose spikes — and the mechanism behind much of the early nausea.
Acts on central appetite circuits to increase satiety and reduce energy intake, the driver of the modest weight loss seen in long-term trials (demonstrated directly in human meal-test studies).
How Pramlintide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Highest hypoglycemia risk; mealtime insulin must be reduced when starting and glucose closely monitored. Boxed-warning population.
Generally avoid — the boxed-warning hypoglycemia risk is unacceptable in those who cannot detect or reliably treat low glucose.
Contraindicated/avoid — pramlintide further slows gastric emptying.
Not established as safe; use only if clearly needed and under specialist supervision. Glycemic management in pregnancy is individualized by a clinician.
Not appropriate — this is a prescription drug indicated as an insulin adjunct, with a boxed warning. Use only for a clinician-confirmed indication.
Pramlintide is used WITH insulin and enhances the risk of insulin-induced severe hypoglycemia, especially in type 1 diabetes and especially in the first weeks. Mealtime insulin is reduced (often by ~50%) when starting, with close glucose monitoring. This is the basis of its boxed warning.
Combining with other agents that lower glucose can additively increase hypoglycemia risk; clinician dose adjustment and monitoring are required.
By slowing gastric emptying, pramlintide can delay the absorption of co-administered oral drugs. Where a rapid onset is needed (e.g. analgesics, oral contraceptives, some antibiotics), take them at least 1 hour before or 2 hours after the pramlintide injection.
Agents that further slow GI motility (e.g. anticholinergics) or other drugs affecting gastric emptying may compound pramlintide's GI effects — clinician review advised.
Tip: Reduce mealtime insulin by ~50% when starting; monitor blood glucose frequently; titrate slowly; ensure the patient and family recognize and can treat hypoglycemia
Tip: Gradual dose titration; usually mild-to-moderate and concentrated in the first weeks, then dissipates
Tip: Slow titration; more common at higher doses and early in treatment
Tip: Often related to glycemic changes early in treatment; report persistent symptoms to a clinician
Tip: Rotate injection sites (abdomen/thigh)
Pramlintide has an evidence score of 5/10 — moderate evidence based on 66 indexed studies, including 2 meta-analyses. An FDA-approved synthetic analog of the beta-cell hormone amylin (brand Symlin), injected before meals as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Honest appraisal: this is a real prescription drug, not a supplement, with genuine but modest efficacy — roughly a 0.3-0.5% HbA1c reduction and ~1-2.6 kg weight loss as an insulin adjunct. It carries a BOXED WARNING for severe insulin-induced hypoglycemia (especially in type 1 diabetes), commonly causes nausea, and requires reducing mealtime insulin when starting. Listed here for reference only; not a supplement and not auto-recommended. Representative study: PMID 29029531.
The commonly studied dose of Pramlintide is Prescription-only, clinician-titrated. Subcutaneous injection immediately before major meals. Type 1 diabetes: typically start 15 µg and titrate to 30-60 µg per meal. Type 2 diabetes (on mealtime insulin): typically start 60 µg and titrate to 120 µg per meal. Reduce mealtime insulin (often by ~50%) when starting. DO NOT self-dose.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Pramlintide is with meals. Take it with food. Injected subcutaneously immediately before each major meal (≥250 kcal or ≥30 g carbohydrate).
Pramlintide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are severe insulin-induced hypoglycemia, nausea, vomiting / anorexia. Use caution if any of these apply to you: Confirmed diagnosis of gastroparesis (slowed gastric emptying would be worsened); Hypoglycemia unawareness; Poor compliance with current insulin regimen or self-monitoring of blood glucose.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Mostly mechanism / observationalAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. Included here for reference only; it is NOT a supplement and is not auto-recommended.
Orforglipron
Mostly mechanism / observationalAn investigational ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. Honest appraisal: the phase-2 data are strong and the first phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it is INVESTIGATIONAL and not yet approved as a general weight-loss medicine, has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), and the expected thyroid C-cell class warning and long-term outcomes are unsettled. It is NOT a dietary supplement; listed here for reference only.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 68 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research